首页> 外文期刊>BMC Genomics >A modified multiplex ligation-dependent probe amplification method for the detection of 22q11.2 copy number variations in patients with congenital heart disease
【24h】

A modified multiplex ligation-dependent probe amplification method for the detection of 22q11.2 copy number variations in patients with congenital heart disease

机译:改良的多重连接依赖探针扩增方法用于检测先天性心脏病患者22q11.2拷贝数变异

获取原文
           

摘要

Copy number variations (CNVs) of chromosomal region 22q11.2 are associated with a subset of patients with congenital heart disease (CHD). Accurate and efficient detection of CNV is important for genetic analysis of CHD. The aim of the study was to introduce a novel approach named CNVplex?, a high-throughput analysis technique designed for efficient detection of chromosomal CNVs, and to explore the prevalence of sub-chromosomal imbalances in 22q11.2 loci in patients with CHD from a single institute. We developed a novel technique, CNVplex?, for high-throughput detection of sub-chromosomal copy number aberrations. Modified from the multiplex ligation-dependent probe amplification (MLPA) method, it introduced a lengthening ligation system and four universal primer sets, which simplified the synthesis of probes and significantly improved the flexibility of the experiment. We used 110 samples, which were extensively characterized with chromosomal microarray analysis and MLPA, to validate the performance of the newly developed method. Furthermore, CNVplex? was used to screen for sub-chromosomal imbalances in 22q11.2 loci in 818 CHD patients consecutively enrolled from Shanghai Children’s Medical Center. In the methodology development phase, CNVplex? detected all copy number aberrations that were previously identified with both chromosomal microarray analysis and MLPA, demonstrating 100% sensitivity and specificity. In the validation phase, 22q11.2 deletion and 22q11.2 duplication were detected in 39 and 1 of 818 patients with CHD by CNVplex?, respectively. Our data demonstrated that the frequency of 22q11.2 deletion varied among sub-groups of CHD patients. Notably, 22q11.2 deletion was more commonly observed in cases with conotruncal defect (CTD) than in cases with non-CTD (P?
机译:染色体区域22q11.2的拷贝数变异(CNV)与患有先天性心脏病(CHD)的患者子集相关。准确有效地检测CNV对于CHD的遗传分析非常重要。该研究的目的是介绍一种名为CNVplex?的新方法,这是一种旨在有效检测染色体CNV的高通量分析技术,并探讨了22q11.2位点的CHD患者中亚染色体不平衡的患病率单一研究所。我们开发了一种新技术CNVplex ?,用于高通量检测亚染色体拷贝数畸变。在多重连接依赖探针扩增(MLPA)方法的基础上进行了改进,引入了加长的连接系统和四个通用引物组,简化了探针的合成并显着提高了实验的灵活性。我们使用110个样品进行了染色体微阵列分析和MLPA广泛表征,以验证该新方法的性能。此外,CNVplex?被用于筛查连续从上海儿童医学中心入组的818位CHD患者中22q11.2位点的亚染色体失衡。在方法开发阶段,CNVplex?检测了先前通过染色体微阵列分析和MLPA鉴定的所有拷贝数畸变,证明了100%的敏感性和特异性。在验证阶段,通过CNVplex?在818例CHD患者中分别检测到39q和22q11.2缺失和22q11.2重复。我们的数据表明22q11.2删除的频率在冠心病患者的亚组之间有所不同。值得注意的是,锥周缺损(CTD)的病例比非CTD的病例更常见22q11.2缺失(P <0.001)。具有更高的分辨率和更多针对所选染色体基因座的探针,CNVplex?还发现了几个个体,它们的CNV很小,并且其他染色体上有改变。 CNVplex?在检测CNV方面具有高灵敏度和特异性,它是MLPA的替代方法,用于批量筛选已知基因组位点中的致病CNV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号